唑来膦酸增加非行走性脑瘫儿童的骨密度:一项随机对照试验
该随机对照双盲试验将24例5至16岁非行走性脑瘫儿童按1:1分配接受两剂唑来膦酸或安慰剂,间隔6个月。唑来膦酸组腰椎骨密度Z评分平均增加0.8 SD(95%CI:0.4;1.2),显著高于安慰剂组的0.0 SD(95%CI:-0.3;0.3)。12个月唑来膦酸增加骨密度Z评分且不影响生长,但首次剂量后严重急性期症状常见且显著。
要点
- 24例非行走性脑瘫儿童完成研究,14例接受唑来膦酸。
- 唑来膦酸组腰椎骨密度Z评分平均增加0.8 SD(95%CI:0.4;1.2),安慰剂组为0.0 SD(95%CI:-0.3;0.3)。
- 唑来膦酸组50%患者出现严重急性期症状,仅见于首次剂量后。
核心结论
- 唑来膦酸治疗12个月显著增加非行走性脑瘫儿童的骨密度Z评分且不影响生长,但首次剂量副作用常见且显著;需要研究更低的首次剂量和长期结局。
研究设计与样本
- 随机、对照、双盲试验,纳入5至16岁非行走性脑瘫儿童,按1:1随机接受两剂唑来膦酸或安慰剂,间隔6个月。
主要发现
- 唑来膦酸组腰椎骨密度Z评分平均增加0.8 SD(95%CI:0.4;1.2),安慰剂组为0.0 SD(95%CI:-0.3;0.3),组间比较显著。
- 侧位远端股骨骨密度Z评分在唑来膦酸组增加更多。
- 唑来膦酸组50%患者出现严重急性期症状,但仅报告于首次剂量后。
- 两组生长参数相似。
关键数值与推荐
- 腰椎骨密度Z评分变化:唑来膦酸组平均增加0.8 SD(95%CI:0.4;1.2),安慰剂组平均变化0.0 SD(95%CI:-0.3;0.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要研究更低的首次剂量和长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Zoledronate appears to reduce fracture rates in children with cerebral palsy (CP), but no previous randomized, controlled trial has been performed to compare the effect of zoledronate to placebo in children with CP. OBJECTIVE: To investigate the effect of zoledronate on bone mineral density (BMD) Z-scores in children with nonambulant CP in a randomized, controlled, double-blind trial. METHODS: Nonambulant children with CP (5 to 16 years of age) were randomized 1:1 to receive 2 doses of zoledronate or placebo at a 6-month interval. BMD Z-score changes at the lumbar spine and the lateral distal femur (LDF) were calculated from dual-energy x-ray absorptiometry scans. Monitoring included weight, bone age, pubertal staging, knee-heel length, adverse events, biochemical markers, and questionnaires. RESULTS: Twenty-four participants were randomized and all completed the study. Fourteen were assigned to zoledronate. The mean lumbar spine BMD Z-score increased 0.8 SD (95% CI: 0.4; 1.2) in the zoledronate group, which was significant when compared to 0.0 SD (95% CI: -0.3; 0.3) in the placebo group. Similarly, the LDF BMD Z-scores increased more in the zoledronate group. Severe acute phase symptoms affected 50% of the patients in the zoledronate group but were reported exclusively after the first dose. Growth parameters were similar in both groups. CONCLUSION: Zoledronate for 12 months increased BMD Z-scores significantly without affecting growth, but first-dose side effects were common and considerable. Studies into lower first doses and long-term outcomes are needed.
引用
- Granild-Jensen JB, Møller-Madsen B, Rackauskaite G, et al. Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2023. PMID: 37235798. doi:10.1210/clinem/dgad299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。